Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Ongoing drug recalls - open right now

Every FDA drug recall whose status is still Ongoing: the firm is still removing product from the market, or the FDA has not yet closed the file. Some were opened years ago and never formally terminated, so check the initiation date as well as the status.

2,760 recalls, newest first.

Class II · Moderate risk

Moxifloxacin Preservative Free Syr

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0040-2023
Class II · Moderate risk

MITOMYCIN INJECTION 0.375 mg/mL SYR

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0039-2023
Class II · Moderate risk

METHYLCOBALAMIN PF 1 ML Injection Solution 5

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0038-2023
Class II · Moderate risk

LAURETH-9 INJ 2% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0034-2023
Class II · Moderate risk

GLYCERIN OPHTHALMIC DROPS 98.5% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0033-2023
Class II · Moderate risk

CEFTAZIDIME INTRAVITREAL 2.25MG/0.1ML Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0030-2023
Class II · Moderate risk

Brilliant Blue G

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0029-2023
Class II · Moderate risk

Autologus Tears Serum Soln Full Strength

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0028-2023
Class II · Moderate risk

ACETYLCYSTEINE OPTH 5% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0027-2023
Class II · Moderate risk

ACETYLCYSTEINE OPTH 10% Solution

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0026-2023
Class II · Moderate risk

SIREtizer Hand Sanitizer

CGMP Deviations and Superpotent Drug: Levels of acetal and acetaldehyde above allowable limits. Additionally, lot 001 was superpotent.

Ongoing Wrong potency / content Southwest Iowa Renewable Energy LLC D-0166-2023
Class II · Moderate risk

Rifampin Capsules

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Ongoing Nitrosamine impurity Akorn, Inc. NDC 61748-018-30 D-1548-2022
Class II · Moderate risk

Rifampin Capsules

Failed impurities/degradation specifications: Finished product exceeds the 5 ppm interim limit for 1-Methyl-4-Nitrosopoperazine (MNP).

Ongoing Nitrosamine impurity Akorn, Inc. NDC 61748-015-30 D-1547-2022

Recalls by year